GLP-1, or {glucagon-like|glucagon like|glucagon) peptide-1, is now emerging as a major focus in healthcare research, largely due to its impressive impact on treating diseases such as second type diabetes and obesity. New studies have demonstrated that in addition to glucose regulation, GLP-1 agonists offer potential for cardiovascular function and